Loading
OKYO Pharma Ltd Stock: price and insider trades · United States
6 insiders bought €119k of shares over the last 90 days, the latest filed 07 Aug 2026.
OKYO Pharma Ltd: what insiders have been doing
Every trade that managers of OKYO Pharma Ltd disclose to SEC (Form 4) is tracked on this page. The company sits in the Health Care sector. The last twelve months, up to 18 October 2026, brought 8 filings signed by 6 insiders.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
With 8 filings in twelve months, the company is quieter than the median of 19 filings across the 5,814 companies we follow on the same exchange. Looking back to 2022, when coverage begins, insiders filed 6 purchases and no sales.
No insider has bought OKYO Pharma Ltd shares on the open market in the past twelve months. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
16
Thresholds
n/a
Buy Volume
€812,627
6 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleGabriele M. Cerrone2 buys
Flavio Mantelli1 buy
Gary S. Jacob1 buy
John P. Brancaccio1 buy
Rajkumar Patil V1 buy
Robert John Dempsey1 buy
Since the insiders bought
- -44.9%Entry US$1.85 · Close at T+365 US$1.02
- -41.1%Entry US$2.65 · Close at T+365 US$1.56
- -48.0%Entry US$3.00 · Close at T+365 US$1.56
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate OKYO Pharma Ltd Strong Buy (bullish), based on 3 analysts. Average price target: US$8.33.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2026FY ended March 2026 · cache
US$1.44
Analyst consensus
3 analystsStrong buy
US$5.00Target US$8.33(+480%)US$13.00
Income statement
EBITDA-US$8.5M
Net income-US$8.9M0.0% margin
Valuation
PER (forward)-2.2x
P/Book6.1x
Beta-0.06
Balance sheet & cash
Market capUS$75.4M
Total debtUS$2.2M
Free Cash Flow-US$5.9M
Profitability & ownership
ROE-263.8%
ROA-43.1%
% insiders31.1%
% institutions20.1%
Last declaration on 29 July 2026
Declarations16 total
3,363 shares@ US$1.490.0072% mcap100.0% of flowCOMMON STOCKSEC:0001493152-26-035212:0
5,000 shares@ US$1.4770.011% mcap21.6% of flowCOMMON STOCKSEC:0001493152-26-034405:0
22,500 shares@ US$1.450.047% mcap1.8% of flowCOMMON STOCKSEC:0001493152-26-034408:0
15,000 shares@ US$1.5390.033% mcap100.0% of flowCOMMON STOCKSEC:0001493152-26-034409:0
3,500 shares@ US$1.400.0071% mcap8.3% of flowCOMMON STOCKSEC:0001493152-26-034406:0
20,000 shares@ US$1.400.040% mcap100.0% of flowCOMMON STOCKSEC:0001493152-26-034236:0
25,000 shares@ US$1.400.050% mcap1.9% of flowCOMMON STOCKSEC:0001493152-26-034084:0
300,000 sharesCOMMON STOCKSEC:0001493152-26-028117:0
499,468 shares@ US$1.5043.8% of flowOrdinary SharesSEC:0001493152-23-038854:0
70,071 shares@ US$1.506.2% of flowOrdinary SharesSEC:0001493152-23-038854:1
16,670 shares@ US$1.5078.4% of flowOrdinary SharesSEC:0001493152-23-034486:0
Canonical exit: 14 Dec 2023 (T+90)
5,800,000 shares@ US$0.07626.0% of flowOrdinary SharesSEC:0001493152-22-014552:0
Canonical exit: 17 Aug 2022 (T+90)
37,500 shares@ US$4.008.8% of flowAmerican Depositary SharesSEC:0001493152-22-014437:0
Canonical exit: 17 Aug 2022 (T+90)
12,500 shares@ US$4.0091.7% of flowAmerican Depositary SharesSEC:0001493152-22-014438:0
Canonical exit: 17 Aug 2022 (T+90)
25,000 shares@ US$3.875.7% of flowAmerican Depositary SharesSEC:0001493152-22-014299:0
Canonical exit: 15 Aug 2022 (T+90)
1,625,000 shares@ US$0.05955.7% of flowOrdinary SharesSEC:0001493152-22-014284:0
Canonical exit: 15 Aug 2022 (T+90)
16 of 16 declarations
About OKYO Pharma Ltd
OKYO Pharma Ltd is a biopharmaceutical company focused on developing treatments for inflammatory diseases and eye disorders. It is listed on NASDAQ under the symbol OKYO.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
